Current phase 1/2 research for neovascular age-related macular degeneration
Authors:
- 1 May 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 26 (3) , 188-193
Abstract
The purpose of this review is to provide an update of phase 1 and 2 clinical trials in neovascular age-related macular degeneration that are either currently underway or recently completed by the end of 2014. Three gene therapy options are currently in early clinical trials, administered via intravitreal (AAV2-sFLT01) or subretinal (AVA-101 and RetinoStat) injection to express angiogenesis inhibitors. Several eye drops are being developed for topical administration for various angiogenic inhibitors, including regorafenib, squalamine lactate, and PAN-90806. Early development of systemic administration options may be intravenous (iSONEP) or oral (X-82). Initial study of local radiation therapy may be via proton beam irradiation or stereotactic radiotherapy. Several intravitreal injections are being studied including human immuno-conjugate molecule (hl-con1), abicipar pegol, PF582, DE-120, ESBA 1008, and REGN2176-3. Numerous treatment options of neovascular age-related macular degeneration are in phase 1/2 clinical trials including gene therapy, eye drops, systemic dosing, localized irradiation, and various intravitreal injections. Future phase 3 trial results will be observed closely to determine which of these therapies will be the next novel treatment of neovascular age-related macular degeneration.Keywords
This publication has 11 references indexed in Scilit:
- Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular DegenerationOphthalmology, 2015
- Stereotactic Radiotherapy for Neovascular Age-Related Macular DegenerationOphthalmology, 2015
- Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinician’s perspectiveCancer Treatment Reviews, 2014
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisThe Lancet Global Health, 2014
- Safety and Biodistribution of an Equine Infectious Anemia Virus-Based Gene Therapy, RetinoStat ® , for Age-Related Macular DegenerationHuman Gene Therapy, 2012
- THREE-YEAR FOLLOW-UP OF A PILOT STUDY OF RANIBIZUMAB COMBINED WITH PROTON BEAM IRRADIATION AS TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATIONRetina, 2012
- Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular DegenerationMolecular Therapy, 2011
- Blockade of sphingosine‐1‐phosphate reduces macrophage influx and retinal and choroidal neovascularizationJournal of Cellular Physiology, 2008
- Age-Related Macular Degeneration and Blindness due to Neovascular MaculopathyArchives of Ophthalmology (1950), 1984
- SENILE MACULAR DEGENERATION: REVIEW OF EPIDEMIOLOGIC FEATURESAmerican Journal of Epidemiology, 1983